Language

Neurology Research

Clinical Research for Neurologic Diseases

The MultiCare Neuroscience Center of Washington has been active in the search for new and innovative treatments for many of the devastating neurologic diseases that affect our community. The MultiCare Research Institute has partnered with the MultiCare Neuroscience Center of Washington to provide research opportunities to our community in many areas of neurologic science including:

Multiple Sclerosis

John Huddlestone, MD and the site are nationally recognized for excellence. He has been involved in clinical trials for more then 2 decades. Trials are conducted at South Sound’s only nationally recognized Multiple Sclerosis Center. The site has participated in trials evaluating

  • First oral medications for treatment of MS
  • Monoclonal antibody therapy in MS
  • Novel therapeutics with specific targets in MS
  • Comparison of Disease Modifying Therapies in MS
  • Long-term follow-up trials after Exposure to Investigational Products

Post-Herpetic Neuralgia pain control

Restless Leg Syndrome control of symptoms

Migraine Headache treatment and suppression

Movement Disorders treatment

Epilepsy

Two Board Certified Epileptologists, Laura Hershkowitz, DO and Laura Lynam, MD offer clinical trials to patients with epilepsy.


The Investigators in Neuroscience medicine include:

Laura Hershkowitz, DO, FACN (Principal Investigator)

John Huddlestone, MD, FAAN (Principal Investigator)

Stacy Donlon, MD

Peter Kwon, MD

Laura Lynam, MD,

Traci Ryan, MD

Yu Zhu, MD, PhD

Neurology Studies Accepting Participants

Adults 

Multiple Sclerosis   

Esteem

Study Number: 109MS401—A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera™ (Dimethyl Fumarate) when used in routine medical practice in the treatment of multiple sclerosis (ESTEEM) to assess the efficacy and safety of TECFIDERA in the United States.

Study Info

Principal Investigator(s) John Huddlestone, MD, FAAN

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449


Sanofi OBS13434

Study Number: OBS13434—A prospective, multi-center, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis.

Principal Investigator(s) John Huddlestone, MD, FAAN

Study Coordinator: Tonya Stigger[email protected], 253-403-1208


OPTIONS

Study Number: MNK14274069—A multicenter, radomized, double-blind, placebo-controlled parallel group, pilot study to assess the efficacy and safety of HP Acthar Gel in subjects with relapsing-remitting multiple sclerosis.

Study Info

Principal Investigator(s):  Stacy Donlon, MD

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449


Fluent

Study Number: CFTY720DUS40 - A 12-month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomakers after treatment with 0.5 mg fingolimod (FTY720) [FLUENT].

Study Info

Principal Investigator(s)Stacy Donlon, MD

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449

Radiologically Isolated Syndrome

ARISE

Study Number: UTSMC ARISE—A multicenter, randomized, double-blinded assessment of Tecfidera in extending the time to a first attack in radiologically isolated sydrome (RISE).

Study Info

Principal Investigator(s)Stacy Donlon, MD

Study Coordinator:  Jarrod Monroe, [email protected], 253-403-7449

Pediatrics  

Absence Seizures

INSYS 103

Study Number: INS011-17-103 - A phase 2, open-label, dose-finding study to assess the efficacy, safety tolerability and pharmaceutical grade synthetic cannabidiol oral solution in pediatric patients with treatment-resistent childhood absence seizures.

Study Info

Principal Investigator(s)Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Infantile Spasms

INSYS 082

Study Number: INS011-16-082 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy with Vigabatrin as Initial Therapy in Patients with Infantile Spasms

Study Info

Principal Investigator(s):  Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Lennox-Gastaut Syndrome

EISAI338

Study Number: E2007-G000-338—A multicenter, double-blind, randomized, placebo-controlled trial with an open-label extension phase of perampanel as adjunctive treatment in subjects at least 2 years of age with inadequately controlled seizures associated with Lennox-Gastaut Syndrome.

Study Info

Principal Investigator(s) Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Dravet Syndrome

Zogenix 1503

Study Number: ZX008-1503—An open-label extension trial to assess the long-term safety of ZX008 (Fenfluramine Hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome.

Study Info

Principal Investigator(s)Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348


Zogenix 1602

Study Number: ZX008-1602 - An open-label trial to assess the safety of ZX008 (Fenfluramine Hydrochloride) oral solution in combination with cannabidiol, as an adjunctive therapy in children and young adults with Dravet Syndrome or Lennox-Gastaut Syndrome.

Study Info

Principal Investigator(s)Steven Phillips, MD 

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Migraines

TEVA

Study Number: TV48125-CNS-10141 - A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous Administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age Inclusive)

Study Info

Principal Investigator(s):  Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Tourette Syndrome

Study Number: NBI-98854-TS2003 - A phase 2b, randomized, double-blind, placebo-controlled, dose optimization study assess the safety, tolerability, and efficacy of NBI-98854 for the treatment of pediatric subjects with Tourette Syndrome.

Study Info

Principal Investigator(s) Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348


NBI-98854-TS2004

Study Number: NBI-98854-TS2004 - Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome

Principal Investigator(s):  Steven Phillips, MD

Study Coordinator:  Cassidy Canorro, [email protected], 253-403-9348

Stroke

Stroke

Stroke - Confidence Trial

Study Number: 2015-CL11003—Carotid stent trial to evaluate the safety and efficacy of the Roadsaver stent used in conjunction with the nanoparasol embolic protections system for patients at increased risk for adverse events from carotid endarterectomy.

Study Info

Principal Investigator(s): Brian Kott, MD

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258